Mendelian randomization: Potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes

Current Opinion in HIV and AIDS

Volumn 5, Issue 6, 2010, Pages 545-559

  He, Weijing ^a,b   Castiblanco, John ^a,b   Walter, Elizabeth A ^b   Okulicz, Jason F ^d   Ahuja, Sunil K ^a,b,c  

^a Veterans Administration   (United States)

^b Department of Medicine ^*  (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Biomarker; chemokine; gene; HIV; Mendelian randomization

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR5; INTERLEUKIN 6;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC MARKER; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENDELIAN RANDOMIZATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; REVIEW;

GENETIC MARKERS; HIV INFECTIONS; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; PROGNOSIS; RANDOM ALLOCATION;

EID: 78049262517     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833f2087     Document Type: Review

References (137)

1. Neaton J, Emery S, Neuhaus J. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997-2010. Curr Opin HIV AIDS 2010; 5.
2. Baker J, Duprez D. Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS 2010; 5.
3. Worm S, Hsue P. Role of biomarkers in predicting CVD risk in the setting of HIV infection? Curr Opin HIV AIDS 2010; 5.
4. Niton D, Landay A. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010; 5.
5. Thomas DC, Conti DV. Commentary: the concept of 'Mendelian randomization'. Int J Epidemiol 2004; 33:21-25.
6. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32:1-22.
7. Ebrahim S, Davey Smith G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet 2008; 123:15-33.
8. Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27:1133-1163.
9. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res 2007; 16:309-330.
10. Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med 2008; 5:e177.
11. Bochud M, Rousson V. Usefulness of Mendelian randomization in observational epidemiology. Int J Environ Res Public Health 2010; 7:711-728.
12. Verduijn M, Siegerink B, Jager KJ, et al. Mendelian randomization: use of genetics to enable causal inference in observational studies. Nephrol Dial Transplant 2010; 25:1394-1398.
13. Glynn RJ. Promises and limitations of Mendelian randomization for evaluation of biomarkers. Clin Chem 2010; 56:388-390.
14. Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with Creactive protein levels and risk of coronary heart disease. JAMA 2009; 302:37-48.
15. Kaslow RA, DorakT, Tang JJ. Influence of host genetic variation on susceptibility to HIV type 1 infection. J Infect Dis 2005; 191 (Suppl 1):S68-77.
16. Hunt P, Carrington M. Host genetic determinants of HIV pathogenesis: an immunologic perspective. Immune correlates of protection, activation and exhaustion. Curr Opin HIV AIDS 2008; 3:342-348.
17. Fellay J. Host genetics influences on HIV type-1 disease. Antivir Ther 2009; 14:731-738.
18. Telenti A, Carrington M. Host factors associated with outcome from primary human immunodeficiency virus-1 infection. Curr Opin HIV AIDS 2008; 3:28-35.
19. An P, Winkler CA. Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet 2010; 26:119-131.
20. Nitsch D, Molokhia M, Smeeth L, et al. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol 2006; 163:397-403.
21. Chen L, Davey Smith G, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Med 2008; 5:e52.
22. Li W, Wang M, Irigoyen P, Gregersen PK. Inferring causal relationships among intermediate phenotypes and biomarkers: a case study of rheumatoid arthritis. Bioinformatics 2006; 22:1503-1507.
23. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986; 1:507-508.
24. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000; 29:722-729.
25. Zhang F, Gu W, Hurles ME, Lupski JR. Copy number variation in human health, disease, and evolution. Annu Rev Genomics Hum Genet 2009; 10:451-481.
26. Perry GH, Ben-Dor A, Tsalenko A, et al. The fine-scale and complex architecture of human copy-number variation. Am J Hum Genet 2008; 82:685-695.
27. Alkan C, Kidd JM, Marques-Bonet T, et al. Personalized copy number and segmental duplication maps using next-generation sequencing. Nat Genet 2009; 41:1061-1067.
28. He W, Kulkarni H, Castiblanco J, et al. Reply to: 'Experimental aspects of copy number variant assays at CCL3L1'. Nat Med 2009; 15:1117-1120.
29. Shostakovich-Koretskaya L, Catano G, Chykarenko ZA, et al. Combinatorial content of CCL3L and CCL4L gene copy numbers influence HIV-AIDS susceptibility in Ukrainian children. AIDS 2009; 23:679-688.
30. Colobran R, Pedrosa E, Carretero-IglesiaL, Juan M. Copy number variation in chemokine superfamily: the complex scene of CCL3L-CCL4L genes in health and disease. Clin Exp Immunol 2010. July 23 [Epub ahead of print]
31. Vickers MA, Green FR, Terry C, et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002; 53:1029-1034.
32. Walston JD, Fallin MD, Cushman M, et al. IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. Hum Genet 2007; 122:485-494.
33. Berrahmoune H, Herbeth B, Siest G, Visvikis-Siest S. Heritability of serum hs-CRP concentration and 5-year changes in the Stanislas family study: association with apolipoprotein E alleles. Genes Immun 2007; 8:352-359.
34. Lange LA, Burdon K, Langefeld CD, et al. Heritability and expression of C-reactive protein in type 2 diabetes in the Diabetes Heart Study. Ann Hum Genet 2006; 70:717-725. (Pubitemid 44530636)
35. Cole SW, Arevalo JM, Takahashi R, et al. Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci USA 2010; 107:5681-5686.
36. Worns MA, Victor A, Galle PR, Hohler T. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels: a study in twins. Genes Immun 2006; 7:600-605.
37. Su S, Snieder H, Miller AH, et al. Genetic and environmental influences on systemic markers of inflammation in middle-aged male twins. Atherosclerosis 2008; 200:213-220.
38. Rahman I, Bennet AM, Pedersen NL, et al. Genetic dominance influences blood biomarker levels in a sample of 12,000 Swedish elderly twins. Twin Res Hum Genet 2009; 12:286-294.
39. Ogbuanu IU, Zhang H, Karmaus W. Can we apply the Mendelian randomization methodology without considering epigenetic effects? Emerg Themes Epidemiol 2009; 6:3.
40. FellayJ, Ge D,ShiannaKV, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009; 5:e1000791.
41. Catano G, Kulkarni H, He W, et al. HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS One 2008; 3:e3636.
42. Dolan MJ, Kulkarni H, Camargo JF, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007; 8:1324-1336.
43. Henry WK, Tebas P, Lane HC. Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. JAMA 2006; 296: 1523-1525.
44. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498-1506.
45. Ness RB, Haggerty CL, Harger G, Ferrell R. Differential distribution of allelic variants in cytokine genes among African Americans and White Americans. Am J Epidemiol 2004; 160:1033-1038.
46. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009; 20:43-59.
47. Gao X, Bashirova A, Iversen AK, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 2005; 11:1290-1292.
48. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282:1907-1911.
49. Portales P, Clot J, Corbeau P. Sex differences in HIV-1 viral load due to sex difference in CCR5 expression. Ann Intern Med 2001; 134:81-82.
50. Planchard D, Loriot Y, Goubar A, et al. Differential expression of biomarkers in men and women. Semin Oncol 2009; 36:553-565.
51. Koesters SA, Matu L, Kiama P, et al. Elevation of immune activation in Kenyan women is associated with alterations in immune function: implications for vaccine development. J Clin Immunol 2004; 24:702-709.
52. Eggena MP, Barugahare B, Okello M, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis 2005; 191:694-701.
53. Kalinkovich A, Borkow G, Weisman Z, et al. Increased CCR5 and CXCR4 expression in Ethiopians living in Israel: environmental and constitutive factors. Clin Immunol 2001; 100:107-117.
54. Zabaleta J, Schneider BG, Ryckman K, et al. Ethnic differences in cytokine gene polymorphisms: potential implications for cancer development. Cancer Immunol Immunother 2008; 57:107-114.
55. Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002; 185:1244-1250.
56. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-852.
57. Gonzalez E, Bamshad M, Sato N, et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999; 96:12004-12009.
58. Singh P, Kaur G, Sharma G, Mehra NK. Immunogenetic basis of HIV-1 infection, transmission and disease progression. Vaccine 2008; 26:2966-2980.
59. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-1440.
60. Huik K, Sadam M, Karki T, et al. CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. J Infect Dis 2010; 201:730-739.
61. Ahuja SK, Kulkarni H, Catano G, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 2008; 14:413-420.
62. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U SA 1999; 96:4581-4585.
63. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000; 14:2671-2678.
64. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 2001; 98:5199-5204.
65. An P, Nelson GW, Wang L, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci USA 2002;
66. Duggal P, Winkler CA, An P, et al. The effect of RANTES chemokine genetic variants on early HIV-1 plasma RNA among African American injection drug users. J Acquir Immune Defic Syndr 2005; 38:584-589.
67. Modi WS, Goedert JJ, Strathdee S, et al. MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. AIDS 2003; 17:2357-2365.
68. Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 2002; 99:13795-13800.
69. Schnabel RB, Baumert J, Barbalic M, et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 2009; 115:5289-5299.
70. Melzer D, Perry JR, Hernandez D, et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 2008; 4:e1000072.
71. Ferreira MA, Mangino M, Brumme CJ, et al. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet 2010; 86:88-92.
72. Reich D, Nalls MA, Kao WH, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet 2009; 5:e1000360.
73. Nalls MA, Wilson JG, Patterson NJ, et al. Admixture mapping of white cell count: genetic locus responsible for lower white blood cell count in the Health ABC and Jackson Heart studies. Am J Hum Genet 2008; 82:81-87.
74. He W, Neil S, Kulkarni H, et al. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 2008; 4:52-62.
75. Kulkarni H, Marconi VC, He W, et al. The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry. Blood 2009; 114:2783-2792.
76. Soranzo N, Spector TD, Mangino M, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 2009; 41:1182-1190.
77. Foster CB, Lehrnbecher T, Samuels S, et al. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000; 96:2562-2567.
78. Fernandez S, Rosenow AA, James IR, et al. Recovery of CD4+ T cells in HIV patients with a stable virologic response to antiretroviral therapy is associated with polymorphisms of interleukin-6 and central major histocompatibility complex genes. J Acquir Immune Defic Syndr 2006; 41:1-5.
79. Nattermann J, Vogel M, Berg T, et al. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology 2007; 46:1016-1025.
80. Saumoy M, Lopez-Dupla M, VelosoS, et al. The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes. AIDS 2008; 22:893-896.
81. Mahajan SD, Agosto-Mojica A, Aalinkeel R, et al. Role of chemokine and cytokine polymorphisms in the progression of HIV-1 disease. Biochem Biophys Res Commun 2010; 396:348-352.
82. Naicker DD, Werner L, Kormuth E, et al. Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis. J Infect Dis 2009; 200:448-452.
83. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000; 97:14467-14472.
84. Oleksyk TK, Shrestha S, Truelove AL, et al. Extended IL10 haplotypes and their association with HIV progression to AIDS. Genes Immun 2009; 10:309-322.
85. Dehghan A, Yang Q, Peters A, et al. Association of novel genetic loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohorts. Circ Cardiovasc Genet 2009; 2:125-133.
86. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors: central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retro-viruses 2004; 20:111-126.
87. Arenzana-Seisdedos F, Parmentier M. Genetics of resistance to HIV infection: role of co-receptors and co-receptor ligands. Semin Immunol 2006; 18:387-403.
88. Lederman MM, Penn-NicholsonA,ChoM,MosierD.Biology ofCCR5 and its role in HIV infection and treatment. JAMA 2006; 296:815-826.
89. Lederman MM, Sieg SF. CCR5 and its ligands: a new axis of evil? Nat Immunol 2007; 8:1283-1285.
90. Corbeau P, Reynes J. CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS 2009; 23:1931-1943.
91. Heredia A, Amoroso A, Davis C, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 2003; 100:10411-10416.
92. Heredia A, Gilliam B, DeVico A, et al. CCR5 density levels on primary CD4 T cells impact the replication and enfuvirtide susceptibility of R5 HIV-1. AIDS 2007; 21:1317-1322.
93. Heredia A, Latinovic O, Gallo RC, et al. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci USA 2008; 105:20476-20481.
94. de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999; 163:4597-4603.
95. Pandrea I, Apetrei C, Gordon S, et al. Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood 2007; 109:1069-1076.
96. Pandrea I, Onanga R, Souquiere S, et al. Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding. J Virol 2008; 82:5501-5509.
97. Mummidi S, Bamshad M, Ahuja SS, et al. Evolution of human and nonhuman primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus. J Biol Chem 2000; 275:18946-18961.
98. Shieh B, Liau YE, Hsieh PS, et al. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol 2000; 12:1311-1318.
99. Kawamura T, Gulden FO, Sugaya M, et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 2003; 100:8401-8406.
100. Salkowitz JR, Bruse SE, Meyerson H, et al. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol 2003; 108:234-240.
101. Hladik F, Liu H, Speelmon E, et al. Combined effect of CCR5-delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 2005; 79:11677-11684.
102. Thomas SM, Tse DB, Ketner DS, et al. CCR5 expression and duration of high risk sexual activity among HIV-seronegative men who have sex with men. AIDS 2006; 20:1879-1883.
103. O'Brien TR, McDermott DH, Ioannidis JP, et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000; 14:821-826.
104. Hendrickson SL, Jacobson LP, Nelson GW, et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. J Acquir Immune Defic Syndr 2008; 48:263-271.
105. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004; 36:565-574.
106. Gabutero E, Moore C, Mallal S, et al. Interaction between allelic variation in IL12B and CCR5 affects the development of AIDS: IL12B/CCR5 interaction and HIV/AIDS. AIDS 2007; 21:65-69.
107. Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2:412-417.
108. Zagury D, Lachgar A, Chams V, et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998; 95:3857-3861.
109. Furci L, Scarlatti G, Burastero S, et al. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 1997; 186:455-460.
110. Zagury D, Lachgar A, Chams V, et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998; 95:3851-3856.
111. Ullum H, Cozzi Lepri A, Victor J, et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. J Infect Dis 1998; 177:331-336.
112. Garzino-Demo A, Moss RB, Margolick JB, et al. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999; 96:11986-11991.
113. Cocchi F, DeVico AL, Yarchoan R, et al. Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA 2000; 97:13812-13817.
114. Ye P, Kazanjian P, Kunkel SL, Kirschner DE. Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment. J Lab Clin Med 2004; 143: 310-319.
115. Murphy PM, Baggiolini M, Charo IF, et al. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52:145-176.
116. Nibbs RJ, Yang J, Landau NR, et al. LD78beta, a nonallelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 1999; 274:17478-17483.
117. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002; 13:455-481.
118. Gornalusse G, Mummidi S, He W, et al. CCL3L Copy number variation and the co-evolution of primate and viral genomes. PLoS Genet 2009; 5: e1000359.
119. Townson JR, Barcellos LF, Nibbs RJ. Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol 2002; 32:3016-3026.
120. Shalekoff S, Meddows-Taylor S, Schramm DB, et al. Host CCL3L1 gene copy number in relation to HIV-1-specific CD4+ and CD8+ T-cell responses and viral load in South African women. J Acquir Immune Defic Syndr 2008; 48:245-254.
121. Degenhardt JD, de Candia P, Chabot A, et al. Copy number variation of CCL3-like genes affects rate of progression to simian-AIDS in Rhesus Macaques (Macaca mulatta). PLoS Genet 2009; 5:e1000346.
122. Rot A, Horuk R. Chapter 9 the Duffy antigen receptor for chemokines. Methods Enzymol 2009; 461:191-206.
123. Mayr FB, Spiel AO, Leitner JM, et al. Racial differences in endotoxin-induced tissue factor-triggered coagulation. J Thromb Haemost 2009; 7:634-640.
124. Mayr FB, Spiel AO, Leitner JM, et al. Duffy antigen modifies the chemokine response in human endotoxemia. Crit Care Med 2008; 36:159-165.
125. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 1999; 133:15-22.
126. Reed WW, Diehl LF. Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. Arch Intern Med 1991; 151:501-505.
127. Freedman DS, Gates L, Flanders WD, et al. Black/white differences in leukocyte subpopulations in men. Int J Epidemiol 1997; 26:757-764.
128. Grann VR, Bowman N, Joseph C, et al. Neutropenia in 6 ethnic groups from the Caribbean and the U.S. Cancer 2008; 113:854-860.
129. Hershman D, Weinberg M, Rosner Z, et al. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 2003; 95:1545-1548.
130. Martineau AR, Newton SM, Wilkinson KA, et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 2007; 117:1988-1994.
131. Grann VR, Ziv E, Joseph CK, et al. Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean. Br J Haematol 2008; 143:288-293.
132. Detels R, Liu Z, Hennessey K, et al. Resistance to HIV-1 infection. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1994; 7:1263-1269.
133. Julg B, Reddy S, van der Stok M, et al. Lack of Duffy antigen receptor for chemokines: no influence on HIV disease progression in an African treatment-naive population. Cell Host Microbe 2009; 5:413-415; author reply 418-419.
134. Walley NM, Julg B, Dickson SP, et al. The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. Cell Host Microbe 2009; 5:408-410; author reply 418-409.
135. Horne KC, Li X, Jacobson LP, et al. Duffy antigen polymorphisms do not alter progression of HIV in African Americans in the MACS cohort. Cell Host Microbe 2009; 5:415-417; author reply 418-419.
136. Winkler CA, An P, Johnson R, et al. Expression of Duffy antigen receptor for chemokines (DARC) has no effect on HIV-1 acquisition or progression to AIDS in African Americans. Cell Host Microbe 2009; 5:411-413; author reply 418-419.
137. He W, Marconi V, Castiblanco J, et al. Response: association of Duffy antigen genotypes with HIV-AIDS susceptibility. Cell Host Microbe 2009; 5:418-419.